corlopam
Pharmaranks rates Corlopam 2.9/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Corlopam (Fenoldopam Mesylate) is a medication used to treat Heart Failure, Malignant Hypertension, Renovascular Hypertension.
Fenoldopam Mesylate · by Hospira
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Fenoldopam Mesylate
- Form
- Injectable
- Strength
- Fenoldopam Mesylate EQ 10MG BASE/ML **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons**
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- heart failure, malignant hypertension, renovascular hypertension
- Manufacturer
- Hospira
- FDA application
- NDA019922
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
- heart failure
- malignant hypertension
- renovascular hypertension
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Corlopam treat?
- Corlopam (Fenoldopam Mesylate) may be used to treat heart failure, malignant hypertension, renovascular hypertension, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Corlopam rated?
- pharmaranks gives Corlopam a composite score of 2.9 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Corlopam?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Corlopam. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Corlopam?
- Corlopam is marketed by Hospira. You can see Hospira's full profile, rating, and other products on pharmaranks.
- Is Corlopam a brand-name or generic drug?
- Corlopam is a brand-name product with the active ingredient Fenoldopam Mesylate.
- Is Corlopam available over the counter?
- No. Corlopam is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Corlopam come in?
- Corlopam is currently marketed as injectable, per the FDA's National Drug Code Directory.
- Is Corlopam FDA-registered?
- Corlopam is on record with the U.S. FDA under application number NDA019922. You can verify this on its official FDA label.
- Has Corlopam been recalled by the FDA?
- Corlopam has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Corlopam safe?
- There's no single safe-or-not verdict. pharmaranks gives Corlopam a recall-safety score of 58/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about FENOLDOPAM MESYLATE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 6 reports naming FENOLDOPAM MESYLATE — the active ingredient in Corlopam, and the FDA flagged 83% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- post procedural complication2 reports
- blood pressure decreased1 reports
- catheter related complication1 reports
- deep vein thrombosis1 reports
- extravasation1 reports
- femoral artery dissection1 reports
- hypotension1 reports
- no adverse reaction1 reports
Read these as a signal, not a rate. A report does not mean FENOLDOPAM MESYLATE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
atacand
Candesartan Cilexetil
bio-tropin
Somatropin
bumex
Bumetanide
bystolic
Nebivolol Hydrochloride
epaned
Enalapril Maleate
hydrochlorothiazide
Hydrochlorothiazide
Compare Corlopam head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
corlopam
58/100